Cancer has been attributed to causing many deaths across the world. This is because it is categorized as one of the chronic diseases that is very expensive to cure. As a result, many organizations have been founded to try and find the cure to the disease that has been contributed to many deaths globally. Many people have also taken key interest in specializing and studying cancer cases in a bid to combat the disease. Clay Siegall is the co-founder and president of the Seattle Genetics which is a center for scientific research and drug development. The center also takes keen interest in helping patients understand the type of diseases affecting them and how to manage or treat it. As such, Clay Siegall vast knowledge in the field of scientific research has brought a lot of change regarding the development of advance drugs to cure chronic diseases like cancer. He has spearheaded the development of antibody-drug conjugates that have been using used in over 60 countries across the world. These are drugs that have helped mitigate and treat many cases of cancer.
According to http://www.bizjournals.com/seattle/blog/health-care-inc/2016/03/seattle-genetics-ambitious-plan-for-12-more-drugs.html, Clay Siegall received a lot of recognition when the then Vice President of the united states of America JoeBiden visited Seattle Genetics. As a result, many media houses have focused on the company and Clay Siegall in particular. He also seeks to grow the company into a multinational entity and produced more effective drugs to curb the spread of cancer. Due to its rapid expansion, the company has opened employment opportunities to over 100 employees adding to the existing number of personnel. Clay Siegall responsibility at the company is to make sure the research being done to develop new drugs meets international standards. He is mandated with releasing tested and proven cancer treatment drugs that have also elevated the name of his company. Research is carried out on a daily basis in a bid to keep on with the emerging market trends and technological advancement. His innovative capabilities made him start capital raising activity in order to enable the research center perform to its fullest. As a result he raised over $1.2billion from the public